Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH17-CD3
- Development stage
- Preclinical
- Lead developer
- NovaRock Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDH17-CD3 is a bispecific antibody (BsAb) developed by NovaRock Biotherapeutics for the treatment of gastrointestinal malignancies, including colorectal, gastric, and pancreatic cancers. The therapeutic acts as a T-cell engager by simultaneously targeting Cadherin-17 (CDH17), a cell-surface protein highly expressed in gastrointestinal tumors but with restricted expression in normal tissues, and the CD3 epsilon subunit of the T-cell receptor complex. By bridging T cells and tumor cells, CDH17-CD3 promotes the formation of immunological synapses, leading to T-cell activation, cytokine release, and the selective lysis of CDH17-positive malignant cells. The program is currently in the IND-enabling phase of development.
- Other names
- CDH17-CD3 bispecific antibodyCDH-17-CD3 bispecific antibodyCDH 17-CD3 bispecific antibodyanti-CDH17/CD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)CDH17 (Cadherin-17)
Beyond the preview
Go deeper on CDH17-CD3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH17-CD3.